Drugs Containing Excipient (Inactive Ingredient) MAGNESIUM OXIDE

Branded drugs containing MAGNESIUM OXIDE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ER Squibb & Sons LLC	PRAVACHOL	pravastatin sodium	0003-5178	MAGNESIUM OXIDE
UCB Inc	UNIVASC	moexipril hydrochloride	0091-3707	MAGNESIUM OXIDE
Haleon US Holdings LLC	NICORETTE	nicotine polacrilex	0135-0241	MAGNESIUM OXIDE
Haleon US Holdings LLC	NICORETTE	nicotine polacrilex	0135-0474	MAGNESIUM OXIDE

Generic drugs containing MAGNESIUM OXIDE excipient

Company	Ingredient	NDC	Excipient
ER Squibb & Sons LLC	pravastatin sodium	0003-5178	MAGNESIUM OXIDE
UCB Inc	moexipril hydrochloride	0091-3707	MAGNESIUM OXIDE
Teva Pharmaceuticals USA Inc	rabeprazole sodium	0093-0064	MAGNESIUM OXIDE
Haleon US Holdings LLC	nicotine polacrilex	0135-0241	MAGNESIUM OXIDE

# Magnesium Oxide Excipient Market Dynamics, Patent Position, and Financial Trajectory

Last updated: August 14, 2026

Magnesium oxide is a mature, low-cost pharmaceutical excipient and active ingredient with stable demand, limited patent protection, and modest pricing power. The market is driven by oral solid-dose manufacturing, antacid and laxative products, mineral supplementation, regional quality requirements, and energy costs associated with calcination. Public companies generally do not report magnesium oxide excipient revenue separately, so financial analysis relies on magnesium-compound disclosures, pharmaceutical-volume trends, commodity data, and supplier economics.

What is the pharmaceutical magnesium oxide market used for?

Magnesium oxide is used in pharmaceuticals as an active ingredient, filler, alkalizing agent, desiccant, mineral supplement, and processing aid. Its commercial value depends heavily on particle size, surface area, reactivity, purity, heavy-metal profile, microbiological control, and compliance with compendial standards.

Use	Commercial role	Typical quality requirement
Antacid	Active pharmaceutical ingredient	Controlled reactivity, assay, heavy metals
Laxative	Active pharmaceutical ingredient	Compendial purity and particle-size control
Magnesium supplement	Active ingredient	Assay, elemental magnesium content
Tablet and capsule production	Excipient or functional mineral	Flow, density, compatibility, low contamination
Powder processing	Filler, adsorbent, alkalizing agent	Particle engineering and moisture control
Pharmaceutical manufacturing	pH adjustment or stabilization	Consistent chemical reactivity

In the United States, magnesium oxide is recognized in FDA databases for pharmaceutical use. Its regulatory treatment depends on whether it is used as an active ingredient or an inactive ingredient. The FDA Inactive Ingredient Database records approved-use precedents by dosage form and route, while OTC products must comply with applicable monographs or obtain approval through a new drug application.[1]

Magnesium oxide is also listed as a food additive and mineral source in other jurisdictions. The European Union identifies magnesium oxide as food additive E530, although food and pharmaceutical standards are not interchangeable.[2]

How large is the magnesium oxide excipient market?

The standalone pharmaceutical-excipient market for magnesium oxide is not separately disclosed in public company filings or government statistics. Available data cover broader magnesium compounds, specialty minerals, or finished pharmaceutical products.

The market is best understood as a small subsegment of a much larger magnesium-compounds industry. Nonpharmaceutical applications, including refractories, agriculture, environmental treatment, animal feed, construction materials, and water treatment, consume substantially more magnesium oxide than pharmaceutical manufacturing.[3]

This structure limits the influence of pharmaceutical demand on global magnesium oxide pricing. Pharmaceutical buyers can require higher-quality material, but the overall commodity price is usually set by industrial demand, production capacity, energy costs, and freight.

What determines pharmaceutical magnesium oxide pricing?

Price differences arise from:

• USP/NF or equivalent compendial certification
• Good Manufacturing Practice controls
• Batch documentation and traceability
• Heavy-metal and elemental-impurity testing
• Particle-size distribution
• Bulk density and flow characteristics
• Low-carbonate or high-reactivity specifications
• Packaging, handling, and release testing
• Regional registration and supplier qualification

Commodity magnesium oxide can be priced close to industrial mineral benchmarks. Pharmaceutical-grade material commands a premium because of qualification, testing, documentation, and lower tolerance for batch variability. The premium is usually more defensible for specialized grades than for standard magnesium oxide powder.

What is the financial trajectory for magnesium oxide excipient suppliers?

The financial trajectory is likely to be stable in volume, modest in nominal growth, and exposed to margin pressure. Pharmaceutical magnesium oxide has limited product differentiation and is generally a low-cost component relative to formulation, packaging, distribution, and regulatory expenses.

Financial driver	Expected effect
Growth in generic oral solids	Positive volume effect
Expansion of magnesium supplements	Positive, but competitive
Energy and fuel inflation	Negative gross-margin effect
Chinese export competition	Negative pricing effect
Qualification of alternate suppliers	Negative switching costs for incumbents
Premium particle-engineered grades	Positive margin effect
Consolidation among pharmaceutical buyers	Negative negotiating leverage
Regulatory testing requirements	Positive for qualified suppliers, negative for unqualified producers

The strongest financial opportunity is not standard magnesium oxide. It is higher-value material with controlled morphology, narrow particle distribution, enhanced flow, low heavy metals, or documented performance in a specific tablet or capsule formulation.

Supplier profitability is closely linked to calcination. Magnesium oxide is produced by heating magnesium carbonate, magnesium hydroxide, or related feedstocks. The process consumes substantial energy, and temperature affects the final material's surface area, reactivity, density, and water absorption. Energy inflation therefore affects both cost of goods and product specifications.[3]

A supplier with integrated mineral access, efficient kilns, local distribution, and pharmaceutical quality systems has a stronger margin position than a distributor purchasing commodity material for resale.

Which companies supply pharmaceutical-grade magnesium oxide?

The supplier base includes magnesium-mineral producers, specialty chemical manufacturers, pharmaceutical excipient distributors, and vertically integrated industrial companies. Publicly visible participants include:

Company or group	Relevant position
Martin Marietta Magnesia Specialties	U.S. producer of magnesium oxide and related magnesium compounds
Nedmag	European producer of magnesium compounds, including pharmaceutical and food-related grades
Konoshima Chemical	Japanese producer of specialty magnesium compounds and functional materials
Tateho Chemical Industries	Japanese manufacturer of high-purity magnesium compounds
Magnesia GmbH and related European suppliers	Specialty magnesium oxide and magnesium hydroxide supply
Chinese producers	Broad range of industrial and pharmaceutical-grade magnesium compounds
Pharmaceutical excipient distributors	Regional sourcing, qualification, repackaging, and technical support

The competitive landscape is fragmented at the production level but more concentrated at the qualified-supplier level. A pharmaceutical manufacturer may have many nominal sources but only two or three approved suppliers for a specific grade.

Supplier qualification creates a degree of customer retention. The protection is commercial rather than intellectual property-based. Switching suppliers can require comparative dissolution testing, stability work, process validation, regulatory documentation, and change-control filings.

What patents protect magnesium oxide excipients?

Standard magnesium oxide has weak composition-of-matter protection. The compound is long established, widely used, and not subject to meaningful basic patent exclusivity.

Patent activity is more likely to involve:

• Controlled particle size
• Porous or high-surface-area magnesium oxide
• Coated particles
• Magnesium oxide combinations with other antacid ingredients
• Sustained-release or chewable dosage forms
• Taste masking
• Improved compressibility
• Manufacturing processes
• Specific therapeutic uses
• Magnesium oxide-containing formulations

These patents generally protect a formulation, manufacturing method, dosage form, or use rather than magnesium oxide itself. The commercial value of a patent depends on claim breadth, proof of infringement, validity, and whether the protected product has meaningful sales.

How strong is the magnesium oxide patent estate?

The patent estate is weak for bulk pharmaceutical-grade magnesium oxide and stronger for selected finished products. A supplier cannot ordinarily prevent competitors from manufacturing standard magnesium oxide merely by holding patents on a particular production process or particle form.

The most defensible technical barriers are often maintained as know-how:

• Calcination temperature profiles
• Feedstock preparation
• Residence time
• Milling and classification
• Surface treatment
• Moisture control
• Packaging conditions
• Analytical release specifications

Trade secrets can protect process performance, but they are difficult to enforce against independent development and do not create product-market exclusivity comparable to a drug patent.

What is the Orange Book status of magnesium oxide?

Magnesium oxide is not an Orange Book-listed innovator product in the same way as a patented prescription drug. The Orange Book lists approved drug products and patent information submitted by applicants under FDA requirements. Magnesium oxide products may be marketed as OTC products, approved drug products, supplements, or generic products depending on the product, claims, dosage form, and regulatory pathway.[4]

The practical distinction is important:

• The excipient itself is not protected by Orange Book listing.
• A finished magnesium oxide drug may be subject to product-specific patents.
• OTC antacid or laxative products may rely on monograph compliance rather than a new molecular-entity patent.
• Dietary supplements are regulated under a different framework from drugs.
• A formulation patent does not automatically restrict all magnesium oxide products.

When does magnesium oxide lose exclusivity?

Standard magnesium oxide has no meaningful remaining composition-of-matter exclusivity. Market exclusivity is instead determined by product classification, formulation patents, regulatory exclusivity, trademarks, supplier qualification, and manufacturing know-how.

For an OTC magnesium oxide product, the relevant commercial barriers are usually:

1. Monograph compliance.
2. Manufacturing and quality-system capability.
3. Brand recognition.
4. Distribution access.
5. Formulation performance.
6. Retail or pharmacy placement.
7. Product-specific patents, if any.

For a prescription product containing magnesium oxide, exclusivity depends on the approved product's patents and regulatory status. A Paragraph IV challenge would target listed patents for the finished drug, not the generally available magnesium oxide ingredient.

Which companies are challenging magnesium oxide patents?

No broad, high-value Paragraph IV campaign is associated with magnesium oxide as a standalone pharmaceutical excipient. Generic competition is established because the active ingredient is old, inexpensive, and widely available.

Litigation risk is more relevant to combination products or branded dosage forms. Potential disputes could involve:

• Extended-release magnesium oxide tablets
• Combination antacid products
• Pediatric formulations
• Chewable or orally disintegrating tablets
• Taste-masked products
• Magnesium oxide products with proprietary release profiles

The absence of a major standalone patent dispute reflects the technical and regulatory maturity of the ingredient. It does not eliminate risk for a specific branded formulation.

What FDA regulatory issues affect magnesium oxide?

FDA compliance risk centers on identity, strength, purity, manufacturing controls, and labeling. Pharmaceutical suppliers must maintain specifications appropriate to the intended use and dosage form. Elemental impurities are particularly relevant because mineral materials can carry lead, arsenic, cadmium, mercury, nickel, or other contaminants depending on the geological source and process.

Relevant regulatory controls include:

• USP/NF monograph compliance where applicable
• FDA Inactive Ingredient Database precedent
• cGMP requirements
• Supplier qualification
• Change control
• Certificate-of-analysis reliability
• Elemental impurity assessment under ICH Q3D principles
• Stability and compatibility testing
• Manufacturing-site inspection readiness

A material can meet a chemical assay while failing a formulation process because of poor flow, variable surface area, excessive moisture uptake, or inconsistent reactivity.

What manufacturing and geographic risks affect supply?

China remains a major source of magnesium compounds and related mineral materials. Europe, Japan, and the United States have established specialty producers, but regional capacity is smaller than the global industrial supply base. Supply risk depends on the exact grade, not only the chemical identity.

United States and Europe

Western suppliers offer advantages in documentation, auditability, customer support, and supply-chain transparency. Their disadvantages are higher energy, labor, compliance, and environmental costs.

China

Chinese suppliers can offer lower production costs and broad capacity. Buyers may face longer qualification cycles, export logistics risk, changing environmental controls, and variability among producers.

Japan

Japanese specialty chemical producers compete through purity, process consistency, particle engineering, and technical support rather than commodity pricing.

Geographic diversification is commercially rational for drug manufacturers with high-volume products. Dual sourcing can reduce disruption risk, but the second supplier must match particle properties and processing performance, not merely chemical assay.

What licensing deals affect magnesium oxide?

No major publicly disclosed licensing transactions appear to control standard pharmaceutical-grade magnesium oxide. Licensing is more likely at the finished-product level, where a branded pharmaceutical company may license a formulation, delivery technology, or regional commercial rights.

For excipient suppliers, commercial relationships usually take the form of:

• Distribution agreements
• Preferred-supplier arrangements
• Technical service contracts
• Long-term supply agreements
• Private-label manufacturing
• Regional agency agreements

These arrangements can create customer concentration and channel advantages without generating patent-based exclusivity.

How does magnesium oxide compare with magnesium hydroxide?

Magnesium oxide and magnesium hydroxide compete in antacid, laxative, supplement, and industrial applications, but they have different technical characteristics.

Attribute	Magnesium oxide	Magnesium hydroxide
Formula	MgO	Mg(OH)2
Relative magnesium content	Higher by weight	Lower by weight
Water reactivity	Generally lower solubility	Different neutralization and suspension behavior
Common pharmaceutical use	Supplements, antacids, laxatives	Antacids, laxatives, suspensions
Processing sensitivity	Calcination history is critical	Precipitation and particle morphology can be critical
Patent exposure	Low for ingredient	Low for ingredient, higher in specialized suspensions
Commercial differentiation	Particle size, reactivity, purity	Suspension stability, particle engineering, taste

Product selection depends on dose, onset, formulation behavior, patient acceptability, and manufacturing process. Magnesium oxide may offer a higher elemental-magnesium payload, while magnesium hydroxide can provide different antacid and suspension properties.

What generic launch scenarios exist for magnesium oxide products?

Generic entry is structurally easy for standard immediate-release tablets, capsules, powders, and conventional OTC products. The main barriers are commercial rather than legal.

Product type	Generic entry risk	Main barrier
Standard tablets	High	Price competition
Capsules	High	Retail access and supply scale
Powder products	High	Packaging and consumer brand
Chewables	Medium	Taste, texture, formulation
Extended-release products	Medium to low	Formulation and patent claims
Pediatric liquids	Medium	Suspension stability and palatability
Combination antacids	Medium	Product-specific formulation
Specialty high-purity excipient	Medium	Supplier qualification

Large pharmaceutical buyers can shift suppliers when specifications are standardized. Smaller manufacturers may remain dependent on distributors because they lack the resources to qualify multiple mineral producers.

What is the revenue exposure for pharmaceutical companies?

For finished-product manufacturers, magnesium oxide generally has low direct cost exposure per dose but can have high operational importance. A supply interruption may stop production even when the ingredient represents a small percentage of product cost.

Revenue exposure is greatest for:

• Branded magnesium supplements
• High-volume OTC antacid portfolios
• Laxative products
• Retail private-label products
• Combination products using magnesium oxide as a central active ingredient

For suppliers, revenue concentration is more difficult to measure because magnesium oxide is usually bundled with magnesium hydroxide, magnesium carbonate, magnesium chloride, and industrial compounds. A producer with a diversified end-market portfolio is less exposed to pharmaceutical pricing pressure.

Key Takeaways

• Magnesium oxide is a mature pharmaceutical ingredient with stable demand and limited patent protection.
• Pharmaceutical demand is a small portion of the broader magnesium-compounds market.
• Standard grades face commodity pricing and strong generic competition.
• Premium margins are available for high-purity, controlled-particle, low-heavy-metal, and process-specific grades.
• Energy costs, calcination efficiency, freight, and Chinese supply materially affect profitability.
• The excipient itself has no meaningful Orange Book exclusivity.
• Paragraph IV risk is low for standard magnesium oxide and concentrated in patented finished formulations.
• Supplier qualification, documentation, and process consistency create the principal commercial barriers.
• Public financial disclosures do not isolate magnesium oxide excipient revenue, making segment-level valuation dependent on broader magnesium-compound and specialty-mineral data.
• The most attractive strategic position is a qualified, geographically diversified supplier of pharmaceutical-grade material with differentiated particle and reactivity specifications.

Frequently Asked Questions

Is magnesium oxide a pharmaceutical excipient or an active ingredient?

It can be either. In antacid, laxative, and supplement products, it is often the active ingredient. In other oral solid formulations, it can function as a filler, alkalizing agent, adsorbent, or processing aid.

Is pharmaceutical-grade magnesium oxide more expensive than industrial magnesium oxide?

Yes. The premium reflects compendial testing, documentation, quality systems, traceability, packaging, and supplier qualification. The premium varies by grade and contract volume.

Can a company patent magnesium oxide?

A company generally cannot obtain broad exclusivity over the established compound itself. It may patent a specific particle form, coating, formulation, manufacturing process, or therapeutic use.

Is magnesium oxide subject to biosimilar competition?

No. Magnesium oxide is a small inorganic molecule, not a biologic. Biosimilar regulations do not apply. Competition comes from generics, OTC equivalents, supplements, and alternative magnesium salts.

What is the main investment risk in magnesium oxide excipients?

The main risk is margin compression from commodity competition and energy costs. Demand volatility is usually less important than grade differentiation, customer concentration, supply qualification, and manufacturing efficiency.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
2. European Commission. (n.d.). EU food additive database: E530 magnesium oxide. https://food.ec.europa.eu
3. U.S. Geological Survey. (2024). Mineral commodity summaries 2024: Magnesium compounds. U.S. Department of the Interior. https://pubs.usgs.gov/periodicals/mcs2024/mcs2024-magnesium-compounds.pdf
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
5. Electronic Code of Federal Regulations. (n.d.). 21 C.F.R. Part 331: Antacid products for over-the-counter human use. https://www.ecfr.gov
6. Electronic Code of Federal Regulations. (n.d.). 21 C.F.R. Part 334: Laxative drug products for over-the-counter human use. https://www.ecfr.gov